![](https://investorshub.advfn.com/uicon/219665.png?cb=1652260119)
Friday, April 17, 2020 2:45:30 PM
BY PR Newswire
— 8:00 AM ET 04/17/2020
We caution that this news release is not making any express or implied claims that we have the ability to eliminate the SARS-CoV-2 virus at this time. We further caution that we have not undertaken any clinical trials.
VICTORIA, April 17, 2020 /PRNewswire/ - IMMUNOPRECISE ANTIBODIES LTD. ( IPATF
Loading...
Loading...
) (the "Company" or "IPA") (OTC QB: IPATF) is pleased to provide an update on its research activities for the novel coronavirus (SARS-CoV-2) which outlines the Company's workflows for their experimental vaccines and therapeutics for the research community.
IPA's multitargeting approach combines various SARS-CoV-2 spike protein forms with the Company's diverse technologies. Hence, IPA anticipates that it can accelerate anti-SARS-CoV-2 human antibody discovery, targeting multiple viral epitopes and mechanisms of viral evasion, by immunizing Ligand's OmniRat® animals using the Company's Rapid Prime™ protocol followed by IPA's B cell Select™ and hybridoma generation in parallel with human, naive phage library screening. Subsequent high-throughput binding assays, computational Artemis™ optimization, and protein interaction analyses permit faster preclinical lead selection.
"In addition to using our antibody discovery platforms for the potentially rapid identification of a diverse panel of fully SARS-CoV-2-specific antibodies, we aim targeting additional novel epitopes which are likely inaccessible to conventional antibody formats by screening our in-house, highly complex, VHH repertoire (collection of variable regions of heavy chain antibodies, a region which binds to the target immunogen)," stated Ilse Roodink, Chairwoman of Talem's Scientific Advisory Committee and Coronavirus Global Project Leader. "Due to the relative high sequence homology of VHHs with human antibodies, extensive humanization is not required and therefore, our discovery strategy mixture will significantly contribute to the fast generation of a monoclonal antibody cocktail with broad epitope coverage and diverse functionalities, which is key to successful development of an effective, long-lasting therapy with a high safety profile."
Apart from the various SARS-CoV-2 spike protein forms which IPA has been producing for use in the therapeutic development, data obtained during the discovery and characterization of lead antibody candidates may be of significant value in the reverse-engineering of vaccine candidates used in the formulation of an effective, but low-risk, vaccine.
Jennifer Bath, Ph. D., has reviewed and approved the scientific disclosure contained in this news release.
About ImmunoPrecise Antibodies Ltd. ( IPATF
Loading...
Loading...
)
ImmunoPrecise is a full-service, therapeutic antibody discovery Contract Research Organization offering species agnostic, multi-format, characterized and engineered, human monoclonal antibodies, on an abbreviated timeframe, for its pharmaceutical clients. For further information, visit www.immunoprecise.com or contact solutions@immunoprecise.com. There is no assurance that ImmunoPrecise will be successful in the development of a vaccine and/or therapeutic against the new coronavirus.
Recent LGND News
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 06/03/2024 08:03:51 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/30/2024 08:03:43 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/18/2024 12:00:48 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/17/2024 11:59:50 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/17/2024 09:45:03 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/16/2024 09:39:38 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/15/2024 11:34:53 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/15/2024 10:01:57 PM
- Form 144/A - Report of proposed sale of securities: [Amend] • Edgar (US Regulatory) • 05/15/2024 06:45:41 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/14/2024 11:42:38 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 05/09/2024 08:11:26 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/07/2024 06:27:20 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/06/2024 10:28:44 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/05/2024 11:12:20 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 03/01/2024 09:09:30 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/29/2024 11:50:51 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/29/2024 11:50:43 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/29/2024 11:50:28 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/29/2024 11:49:56 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 02/28/2024 11:05:31 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 02/28/2024 10:43:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/27/2024 12:24:01 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/17/2024 01:10:38 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/17/2024 01:10:27 AM
Last Shot Hydration Drink Announced as Official Sponsor of Red River Athletic Conference • EQLB • Jun 20, 2024 2:38 PM
ATWEC Announces Major Acquisition and Lays Out Strategic Growth Plans • ATWT • Jun 20, 2024 7:09 AM
North Bay Resources Announces Composite Assays of 0.53 and 0.44 Troy Ounces per Ton Gold in Trenches B + C at Fran Gold, British Columbia • NBRI • Jun 18, 2024 9:18 AM
VAYK Assembling New Management Team for $64 Billion Domestic Market • VAYK • Jun 18, 2024 9:00 AM
Fifty 1 Labs, Inc Announces Acquisition of Drago Knives, LLC • CAFI • Jun 18, 2024 8:45 AM
Hydromer Announces Attainment of ISO 13485 Certification • HYDI • Jun 17, 2024 9:22 AM